Sanja Zepcan, PharmD, BCPS, BCOP

Compare revimumab and ziftomib dosing, food rules, tablet crushing, PPI interactions and half-life—key counseling tips to boost patient adherence.

Pharmacists compare revumenib and ziftomenib in AML—QTc thresholds, CYP3A4 interactions, acid suppression limits, and differentiation syndrome monitoring to optimize safety.

Choosing revimumab vs ziftomab in NPM1 AML depends on KMT2A status, transplant plans, drug interactions, adherence, and QTc monitoring.

Menin inhibitors show promising AML responses—revumenib enables remissions and transplant bridging, while new combinations target KMT2A and NPM1.

Menin inhibitors offer new hope in relapsed KMT2A/MP1 AML, controlling disease to reach remission and allogeneic stem cell transplant.

Learn how pharmacists guide AML care, from patient education to mutation-targeted menin inhibitors like revumenib and ziftomenib.

ASCO guidelines reshape multiple myeloma care with quadruplet induction, earlier CAR T-cell therapy and bispecifics, and selective smoldering treatment.